Search

Physician-scientist Tobias Hohl studies the molecular pathogenesis of human fungal pathogens and how the immune system responds to them.

… The focus of my research program is to decipher the molecular and cellular basis of immunity against Candida and Aspergillus species , major causative agents of invasive mycoses in patients with cancer. We have developed fluorescence-based reporters of fungal physiology to examine the outcome of fungal

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.

… The goal of our research program is to understand the detailed mechanisms by which a cancer cell can develop resistance to therapies targeting its oncogenic driver; and to exploit those findings to elucidate the biology of cancer and identify more effective treatments for cancer patients. The focus of

The Nikolov laboratory focuses on the structural, biophysical, and biochemical characterization of the molecular mechanisms of cell-cell interactions and signal transduction across the plasma membrane.

… Research in our laboratory aims to characterize the molecular mechanisms underlying cell-to-cell interactions and signal transduction across the cell membrane. We are particularly interested in understanding how receptors located on the surface of developing axons and neurons interact with extracellular

Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.

… Omar Abdel-Wahab is the Chair of SKI Molecular Pharmacology Program and an Attending Physician on the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. Omar Abdel-Wahab, MD Chair, Molecular Pharmacology Program, SKI; Evnin Family Chair in Molecular Pharmacology

The Osorio Lab studies the mechanisms of antibody-mediated immunity, with a focus on myeloid cell reprograming to advance cancer immunotherapies.

… The Osorio lab investigates the mechanisms underlying antibody-mediated immunity, and how we can leverage these insights to develop durable and effective antibody-based immunotherapies. Our research focuses on harnessing the untapped potential of the innate immune system – particularly the myeloid compartment

The Pillarsetty Laboratory develops bioactive radiopharmaceuticals and fluorophores for molecular characterization and targeted treatment of cancer.

… Targeted Theranostics Laboratory Molecularly targeted therapy modulates a dysregulated target(s) and/or biologic pathway(s) that provides survival advantage for cancer cells. This targeting enables achieve selective destruction of cancer cells while minimizing harm to normal cells. We work on the development

Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.

… The Kharas lab is working to identify critical pathways in both normal and leukemic hematopoietic cells. Michael G. Kharas, PhD Professor PhD, University of California Irvine Achievements Leukemia and Lymphoma Society Career Development Award (2017) Alex Lemonade Stand Foundation ‘A’ Award (2016) American

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

… My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children. Nai-Kong V. Cheung, MD, PhD Enid A. Haupt Chair in Pediatric Oncology, Pediatrics Professor MD, PhD (Immunology), Harvard Medical School Email [email protected] Laboratory phone 646-888

Physician-scientist Christopher A. Klebanoff studies T cell immunobiology with an emphasis on adoptive T cell immunotherapy for the treatment of solid malignancies.

… A form of cancer immunotherapy termed adoptive T cell transfer (ACT), in which a patient’s own T cells are engineered to recognize and attack cancer cells, can induce durable complete remissions in patients with advanced hematologic malignancies. By contrast, a similar approach has thus far failed to

Biostatistician Colin Begg has research interests spanning cancer epidemiology and statistical methods that are applicable to clinical research more broadly.

… Dr. Begg has research interests spanning cancer epidemiology and statistical methods that are applicable to clinical research more broadly. In recent years Dr. Begg has been developing methods to identify etiologically distinct cancer sub-types, statistical tests of clonal relatedness of pairs of tumors